Clinuvel granted orphan designation
Tuesday, 29 July, 2008
Clinuvel Pharmaceuticals' [ASX: CUV] lead compound afamelanotide (CUV1647) has been granted orphan-drug designation by the US FDA.
Afamelanotide is a photoreceptive drug designed for use in the management of erythopoietic porphyrias, a rare group of metabolic disorders which cause phototoxicity.
Orphan-drug designation allows for an accelerated review process by the FDA, seven-year exclusivity once approval is obtained, and various tax benefits and fee exemptions.
Afemelanotide is also being developed as a treatment for other UV-related skin disorders and for cancer prophylaxis.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
